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Care of patients with a diagnosis of chronic obstructive pulmonary disease: a 
cluster randomised controlled trial 
Abstract 
Objective: To evaluate a partnership model of care for patients with a diagnosis of chronic obstructive 
pulmonary disease (COPD). Design, setting and participants: Cluster randomised controlled trial with 
blinded outcome assessment of 44 general practices in south-western Sydney comprising 451 people 
with a diagnosis of COPD, conducted between 2006 and 2009. Intervention: Participants from intervention 
group practices were visited at their home by a registered nurse with specific training in COPD care who 
worked with the general practitioner, the patient and other health professionals to develop and implement 
an individualised care plan based on best-practice guidelines. Participants from control group practices 
received usual care. Main outcome measures: The primary outcome was disease-related quality of life 
measured using the St George's Respiratory Questionnaire (SGRQ) at 12-month follow-up. Other 
outcomes were overall quality of life, lung function, smoking status, immunisation status, patient 
knowledge of COPD, and health service use. Results: Of the 451 participants, 257 (57.8%) were confirmed 
as having COPD on post-bronchodilator spirometry. Follow-up was completed for 330 patients (73.2%). At 
12 months, there was no statistically significant difference in the mean SGRQ scores between 
intervention and control groups (38.7 v 37.6; difference, 1.1; 95% CI, - 1.53-3.74; P =0.41) or in measures 
of quality of life, lung function and smoking status. Compared with the control group, in the intervention 
group, attendance at pulmonary rehabilitation was more frequent (31.1% v 9.6%; OR, 5.16; 95% CI, 
2.40-11.10; P =0.002) and the mean COPD knowledge score was higher (10.5 v 9.8; difference, 0.70; CI, 
0.10-1.21; P=0.02). Conclusion: The nurse-GP partnership intervention did not have an impact on disease-
related quality of life at 12-month follow-up. However, there was evidence of improved quality of care, in 
particular, in attendance at pulmonary rehabilitation and patient knowledge of COPD. 
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hronic obstructive pulmo-
nary disease (COPD) is a
lead ing cause  o f  death
worldwide.1 Guidelines for care of
COPD provide recommendations
for slowing disease progression and
optimising function in people with
COPD.2,3 The key interventions are
smoking cessation, pulmonary reha-
bilitation, influenza vaccination,
optimising medicines, patient edu-
cation and effective management of
exacerbations.
There is a need for effective
approaches to implementation of
evidence-based treatment in pri-
mary care, where many patients
with COPD are managed. Nurses,
either within the practice or visiting
to provide specialised care, could
have a role in improving manage-
ment of COPD, including by helping
to implement planned care.
A review of nine randomised tri-
als of nurse-led chronic disease
management for COPD concluded
that there was no evidence of
improvements in patients’ health-
related quality of life, psychological
wellbeing, disability or pulmonary
function.4 A more recent Cochrane
review of nine trials of outreach
programs involving nurse home vis-
its to COPD patients concluded that
providing support and education,
monitoring health status and pro-
viding liaison with physicians
resulted in improved disease-spe-
cific quality-of-life measures but
had variable effects on hospitalisa-
tion.5 A New Zealand study, which
was not included in the Cochrane
Review as it did not have a substan-
tial home-visit component, resulted
in reduced hospital admissions and
bed-days, and significant improve-
ments in quality of life and lung
function.6
A previous randomised trial con-
ducted by members of our group
evaluated the effect of a brief nurse-
led intervention, including develop-
ment of a care plan, after discharge
from hospital on clinical outcomes
in patients with COPD.7 There was
no difference between groups in
health-related quality of life or hos-
pital admissions. Patients in the
intervention group had higher
knowledge scores and were more
satisfied with their care. In that
study, less than a third of the gen-
era l  prac tit ioners  remembered
receiving the care plan, and there
were no differences in GP visits or
management.
We hypothesised that more active
engagement of the GPs, and the
nurse having a role not only in
developing but also implementing a
plan of care, would be more effec-
tive. Therefore, this study evaluated
the effectiveness, compared with
usual care, of a nurse with training
in COPD care working in partner-
ship with the patient and their GP
to develop and implement an
individualised care plan based on
clinical practice guidelines.
Methods
Research design
A cluster randomised trial, with ran-
domisation at the level of the practice,
was conducted to avoid contamination
between intervention and control
groups. The study protocol has been
published.8 Recruitment started in
December 2006 and follow-up was
completed in May 2009. Ethics
approval was from University of New
South Wales and Sydney South West
Area Health Service human research
ethics committees.
Recruitment
GPs were recruited from a list of 256
GPs from practices in south-western
Sydney who had previously taken part
Care of patients with a diagnosis of chronic 
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C Objective:  To evaluate a partnership model of care for patients with a diagnosis of chronic obstructive pulmonary disease (COPD).
Design, setting and participants:  Cluster randomised controlled trial with blinded 
outcome assessment of 44 general practices in south-western Sydney comprising 
451 people with a diagnosis of COPD, conducted between 2006 and 2009.
Intervention:  Participants from intervention group practices were visited at their 
home by a registered nurse with specific training in COPD care who worked with 
the general practitioner, the patient and other health professionals to develop and 
implement an individualised care plan based on best-practice guidelines. 
Participants from control group practices received usual care.
Main outcome measures:  The primary outcome was disease-related quality of life 
measured using the St George’s Respiratory Questionnaire (SGRQ) at 12-month 
follow-up. Other outcomes were overall quality of life, lung function, smoking 
status, immunisation status, patient knowledge of COPD, and health service use.
Results:  Of the 451 participants, 257 (57.8%) were confirmed as having COPD on 
post-bronchodilator spirometry. Follow-up was completed for 330 patients 
(73.2%). At 12 months, there was no statistically significant difference in the mean 
SGRQ scores between intervention and control groups (38.7 v 37.6; difference, 1.1; 
95% CI,  1.53–3.74; P = 0.41) or in measures of quality of life, lung function and 
smoking status. Compared with the control group, in the intervention group, 
attendance at pulmonary rehabilitation was more frequent (31.1% v 9.6%; OR, 5.16; 
95% CI, 2.40–11.10; P = 0.002) and the mean COPD knowledge score was higher 
(10.5 v 9.8; difference, 0.70; CI, 0.10–1.21; P = 0.02).
Conclusion:  The nurse–GP partnership intervention did not have an impact on 
disease-related quality of life at 12-month follow-up. However, there was evidence 
of improved quality of care, in particular, in attendance at pulmonary rehabilitation 
and patient knowledge of COPD.
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in research or who attended continu-
ing medical education activities held
by local Divisions of General Practice.
GPs on the list were approached by
mail, followed by a telephone call
from one of the researchers (N Z or
S V). Inclusion criteria for GPs were
using an electronic prescribing system
and having seen COPD patients in
the past 12 months.
Participating GPs, who were not
aware of their allocation status at the
time of patient recruitment, were
asked to search their electronic records
to identify patients who had been pre-
scribed medications used for COPD
defined as inhaled 2 agonists, inhaled
corticosteroids, ipratropium bromide,
tiotropium, oral theophylline and oral
corticosteroids. Patients were eligible if
they were aged between 40 and 80
years, had been prescribed one or
more of these medications, and had
seen the GP in the previous 12
months. GPs were then asked to man-
ually review the list generated and
identify patients that they considered
to have a diagnosis of COPD, emphy-
sema or chronic bronchitis, including
those that they considered to have
coexisting problems, such as asthma.
GPs were asked to include patients
regardless of how or where the diag-
nosis had been made, and information
on the diagnostic process was not col-
lected. Patients were excluded if they
did not speak English or had signifi-
cant cognitive impairment.
Letters were sent from the practice
to eligible patients inviting them to
take part in the study. Two fortnightly
reminders were sent to the non-
responding patients.
Randomisation
A researcher who took no further part
in the study randomised practices to
intervention or control groups, with
allocation concealment. Details of the
randomisation process have been
published previously.8
Intervention
Two nurses, specifically recruited and
trained for this study, worked in part-
nership with GPs to implement the
intervention. In the service model, the
nurses were external to the practice
and visited patients in their homes.6
The training program for the nurses
involved attendance at a 2-day work-
shop where the following topics were
presented by expert clinicians: patho-
physiology of COPD; assessment of
COPD; spirometry; smoking cessa-
tion; management of COPD accord-
ing to Australian and New Zealand
guidelines;3 the role of pulmonary
rehabilitation in the management of
COPD; and the management of exac-
erbations. The training covered the
principles and practice of motivational
interviewing and self-management
support. Following the training, there
were monthly meetings lasting 1–2
hours between the nurses and mem-
bers of the study team (N Z and S V),
and feedback from a respiratory phy-
sician on the quality of their spiro-
metry (G M). The intervention and its
implementation are described online
at mja.com.au. The intervention was
delivered between 2007 and 2009.
Control
GPs in the control-group practices
were provided with a copy of the
COPD guidelines, and their patients
received usual care, which was
defined as processes normally fol-
lowed by the GP and the patient
regarding review, pharmacological
therapy and management of COPD.
Outcome measures
The primary outcome measure was
disease-related quality of life, meas-
ured using the St George’s Respira-
tory Questionnaire (SGRQ) at 12
months after recruitment. The SGRQ
is a validated instrument designed to
measure the impact of respiratory dis-
eases (in particular, asthma and
COPD) on an individual’s life.9 The
SGRQ is scored from zero to 100,
where zero indicates best quality of
life and 100, the worst. A change in
score of  4 is considered to be clini-
cally significant.9,10
Other outcome measures were
overall quality of life (measured using
the 12-item Short Form Health Sur-
vey [SF-12], which is a generic meas-
ure of health impairment); lung
function; smoking status; immunisa-
tion status for influenza and pneumo-
coccus; attendance at pulmonary
rehabilitation; patient knowledge of
COPD; and health service use. For
those patients with COPD on spiro-
metry, classification of severity was
made using Global Initiative for
Chronic Obstructive Lung Disease
(GOLD) criteria.2 The patient’s
knowledge of COPD was measured
by a 12-item scale developed for a
previous project.7 This scale asked
patients if they knew the name of
their chest condition, which immuni-
sations were helpful in reducing the
risk of exacerbations, patient actions
that could help control symptoms and
improve quality of life, and symptoms
suggestive of an exacerbation. Correct
answers scored one point and incor-
rect answers zero points, resulting in a
score out of 12. The scale has face
validity but has not been subjected to
validation testing.
Outcomes, with the exception of
the SGRQ, were measured at three
points in time: recruitment (base-
line), 6 months and 12 months after
randomisation. The SGRQ was
measured at baseline and 12 months.
Assessments were conducted at the
participant’s residence or at the GP’s
practice (according to patient prefer-
ence) by project officers (O H and I H)
who took no part in the intervention
and were blind to group allocation.
Analysis
The analysis was based on intention
to treat. The effect of the intervention
on continuous variables was esti-
mated and tested in SAS, version 9.2
(SAS Institute Inc) using a mixed-
model procedure, in which time and
treatment groups were fixed-effect-
and subject-nested within practice
clusters, and time points within sub-
jects were random effects. For the
binary outcome variables, a general-
ised estimating equation method was
separately implemented at each time
point that incorporated practice clus-
ter effect. The analyses for continuous
and binary variables were adjusted for
baseline values.
Given that the measurement of
outcome variables (with the exception
of SGRQ score) was done at baseline,
6 and 12 months, an analysis was
done to examine whether a time and
intervention group interaction was
present. This was found not to be the
case, so baseline and 12-month meas-
ures are reported.
Sample size
The sample size calculation was
based on detecting a between-group
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difference in SGRQ score of  4 at 12
months after intervention.9,10 After
adjusting for clustering, the number
per group required to detect this dif-
ference with 80% power at the 5%
significance level was estimated to be
200 per group, based on an intraclus-
ter coefficient of 0.01 and a resultant
design effect of 1.09 for a cluster size
of 10. Details of the sample size calcu-
lation have been published.8
Results
We recruited 56 GPs from 44 practices
in south-west Sydney. The mean age
of the GPs was 52.3 years and 47%
were men. Participating GPs searched
their patient records, identifying 1144
patients who were eligible and invited
to participate. Of these, 451 (39.4%)
patients were recruited and provided
baseline data, 330 (73.2%) of whom
completed the 12-month assessment
(see the flow diagram online at
mja.com.au).  Characterist ics of
patients completing the 12-month
assessment compared with those lost
to follow-up were: age, 65.3 v 64.7
years; men, 47.3% v 49.6%; spoke
English at home, 79.1% v 79.7%; and
current smokers, 30.2% v 31.1%.
There was a lower rate of confirmed
COPD than expected. Of the 451 par-
ticipants, 445 (98.7%) were able to
perform baseline spirometry and, of
these, 257 (57.8%) were confirmed to
have COPD.11
Baseline characteristics of partici-
pants are shown in Box 1. There was
a higher rate of confirmed COPD,
lower forced expiratory volume in 1
second and fewer comorbidities in
the intervention group, but the
groups did not differ on the SGRQ or
other characteristics.
There were no statistically signifi-
cant between-group differences in the
primary outcome measure (SGRQ) or
in overall quality of life, respiratory
function or smoking status at 12-
month follow-up (Box 2). The intra-
cluster correlation for the SGRQ cal-
culated using the mixed-model
procedure was 0.03. In continuing
smokers, there was a trend towards
fewer cigarettes smoked per day in
the intervention group.
In process-of-care outcomes, more
patients in the intervention group
reported having attended a pulmo-
nary rehabilitation program. This dif-
ference was statistically significant
(P = 0.002). Data were not collected
on whether they completed the pro-
gram. There was a higher rate of
patients in the intervention group
reporting being vaccinated for influ-
enza and pneumococcus, but neither
difference was statistically significant.
There was no difference in the fre-
quency of either GP or hospital or
emergency department attendance in
the previous 3 months. The COPD
knowledge score was statistically sig-
nificantly higher in the intervention
group (P = 0.02) (Box 3).
Discussion
A notable finding was that only 57.8%
of patients identified as having COPD
and being eligible for the study were
confirmed as having the condition
according to spirometric criteria. We
have previously published baseline
analyses of the accuracy of diagnosis
showing that having a spirometer in
the practice was not predictive of
agreement between the clinical and
spirometric diagnoses.11 Older patient
age was associated with correct diag-
nosis, while higher numbers of
2 Disease-related and overall quality of life, respiratory function and smoking status at 12-month follow-up 
Outcome
Intervention 
(n = 234 randomised)*
Control 
(n = 217 randomised)* Difference (95% CI) P 
SGRQ score 38.7 (19.0) 37.6 (19.1) 1.1 ( 1.53–3.74 ) 0.41
SF-12 score
Physical component 36.3 (11.6) 36.7 (13.0)  0.4 ( 2.1–1.3) 0.61
Mental component 51.0 (11.2) 51.5 (11.3)  0.5 ( 2.3–1.2) 0.55
FEV1 post-bronchodilator, percentage of predicted (SD) 72.3% (24.1%) 73.1% (24.4%)  0.8 ( 3.3–1.7) 0.51
No. of current smokers (%) 47/161 (29.2%) 37/168 (22.0%) 1.3 (0.6–2.5)† 0.52
No. of cigarettes per day (SD) (n = 157) 15 (8) 18 (11)  3 ( 6.0–0.04) 0.05
* Figures are mean (SD) unless stated otherwise stated. † Odds ratio (95% CI). FEV1 = forced expiratory volume in 1 second. SGRQ = St George’s Respiratory 
Questionnaire. SF-12 = 12-item Short Form Health Survey.  ◆
1 Baseline characteristics of groups
Characteristic Intervention (n = 234) Control (n = 217)
Mean age, years (SD) 65.8 (10.3) 64.4 (10.3)
No. of men (%) 110 (47.0%) 106 (48.8%)
No. of current smokers (%) 74 (31.6%) 61 (28.1%)
No. with FEV1/FVC < 0.7 (%) 146 (62.4%) 111 (51.2%)
GOLD stage: no. of patients (%)
Stage 1 28 (12.0%) 20 (9.2%)
Stage 2 70 (29.9%) 63 (29.0%)
Stage 3 38 (16.2%) 19 (8.8%)
Stage 4 10 (4.3%) 9 (4.1%)
Mean SGRQ score (SD) 42.0 (18.3) 42.0 (19.4)
Mean COPD knowledge score (SD) 8.9 (1.4) 8.9 (1.5)
No. vaccinated for influenza (%) 156 (66.7%) 155 (71.4%)
No. vaccinated for pneumococcus (%)  137 (58.5%) 123 (56.7%)
Mean no. of comorbidities 3.6 ( 4.1 (
Mean SF-12 score (SD)
Physical component 36.4 (11.1) 36.6 (12.5)
Mental component 49.3 (11.7) 49.0 (11.4)
FEV1= = forced expiratory volume in 1 second. FVC = forced vital capacity. SGRQ = St George’s 
Respiratory Questionnaire. GOLD = Global Initiative on Obstructive Lung Disease; stages describe 
severity of disease from mild (Stage 1) through to severe (Stage 4). COPD = chronic obstructive 
pulmonary disease. SF-12 = 12-item Short Form Health Survey. ◆
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comorbidities were associated with
misdiagnosis.
The study found no between-group
difference in the primary outcome
measure (SGRQ) and also no
between-group differences in SF-12
score, lung function or smoking rates
at 12-month follow-up. Differences in
lung function would be unlikely to be
apparent within 12 months, so longer
term follow-up would be needed to
show change in this outcome measure.
Smoking cessation is a key priority for
COPD care, and about 30% of partici-
pants in the study were smokers.
However, we did not succeed in get-
ting more patients in the intervention
group to quit. Among continuing
smokers, there were fewer cigarettes
smoked in the intervention versus the
control group, but as the mean differ-
ence was only three cigarettes per day,
this would be unlikely to produce a
health benefit.
There was greater attendance at a
pulmonary rehabilitation program
by patients in the intervention
group, indicating improved delivery
of evidence-based care. It has been
shown that participation in pulmo-
nary rehabilitation leads to improve-
ments in health-related quality of
life (measured by the SGRQ) at the
end of the program.12 The fact that
these benefits were not apparent in
our study may be due to insufficient
numbers of participants attending
an d/or  completing pu lmonary
rehabilitation, or due to improve-
ments evident at the end of the
program not being sustained to the
outcome measurements points. The
higher rate of influenza and pneu-
mococcal vaccination in the inter-
vention compared with the control
group suggests improved delivery
of care, but these differences were
not statistically significant. Patients
in the intervention group had
higher COPD knowledge scores,
presumably related to the educa-
t ion prov ided by the  nurses,
although the clinical importance of
this is uncertain.
Our study had some limitations.
The participating practices were
drawn from a list of practices that had
previous involvement in research or
teaching, or that had attended contin-
uing educational events. Therefore,
they may not have been entirely rep-
resentative of all practices in Aus-
tralia. Sources of potential bias are
that the uptake of the invitation to
participate was 39.4%, and that 26.8%
of participants randomised were lost
to follow-up at 12 months.
The criterion for entry into the
study was having a diagnosis of
COPD and we did not require this to
be confirmed on spirometry. This
reflects the real-world situation in pri-
mary care, where the diagnosis is
often made and treatment initiated on
clinical grounds.13-15 The rate of mis-
classification was similar to that of
other studies from Australia16 and
internationally.17,18
However, the intervention compo-
nents were based on evidence of
effectiveness from studies in patients
with COPD confirmed on spirometry,
and the intervention may only have
been effective in this subgroup of par-
ticipants. A subgroup analysis, which
examined the outcomes for the 257
patients who had COPD confirmed
on spirometry, was similar to the
intention-to-treat analysis, with no
statistically significant differences at
12 months in SGRQ, SF-12, lung
function or smoking rates. As the
numbers were smaller, there was a
risk of a type 2 error, and this risk was
further increased as the intracluster
correlation found for the SGRQ (0.03)
was slightly higher than our estimate
of 0.01.18
Our findings are consistent with
the current uncertainty about the
effect of disease-management pro-
grams, including self-management
support, for COPD. While some stud-
ies have shown benefit,6,19 others,
including a recently published study
of comprehensive care management
to prevent COPD hospitalisations,
have had negative results.20
The lack of impact from the inter-
vention on prevalence of smoking
demonstrates the need to continue to
develop and test interventions to
encourage smoking cessation in people
with COPD. There is continuing
debate about whether performing
spirometry and informing patients of
abnormal results increases smoking
cessation.21,22 There has been promis-
ing research on the use of lung age as
a tool to encourage quitting, but this
has not been studied in patients with
COPD.23 The evidence base on smok-
ing-cessation interventions for people
with COPD is very limited,24 and
there is a need for studies that evalu-
ate both psychosocial approaches and
innovative ways of using pharmaco-
therapy.25
Pulmonary rehabilitation has the
potential to improve health-related
quality of life, but even in the inter-
vention group, less than a third of
patients attended pulmonary rehabili-
tation. This was consistent with previ-
ous research reporting uptake of
33%–39% in pulmonary rehabilitation
programs provided in outpatient clin-
ics.26 There is evidence that home-
based programs may be as effective as
supervised hospital outpatient-based
programs,27,28 but studies on imple-
mentation are lacking. Finally, there is
the question of whether the nurse–GP
partnership intervention to imple-
ment evidence-based care would have
been effective if it had been imple-
mented with patients at an early stage
3 Process-of-care outcomes at 12-month follow-up 
Patient outcome Intervention* Control* Odds ratio (95% CI) P 
No. vaccinated for influenza (%) 131/161 (81.4% ) 129/167 (77.2%) 1.88 (0.88–4.02) 0.13
No. vaccinated for pneumococcus (%) 117/161 (72.7%) 103/167 (61.7%) 1.64 (0.93–2.89) 0.09
No. attended pulmonary rehabilitation program (%) 50/161 (31.1%) 16/167 (9.6%) 5.16 (2.40–11.10) 0.002
No. visited general practitioner in preceding 3 months (%) 148/160 (92.5%) 150/169 (88.8%) 1.59 (0.70–3.61) 0.27
No. used hospital or emergency department service in 
preceding 3 months (%)
27/161 (16.8%) 24/169 (14.2%) 1.21 (0.70–2.10) 0.50
COPD knowledge score (SD) 10.5 (2.0) 9.8 (1.9) 0.7 (0.1–1.2)† 0.02
COPD = chronic obstructive pulmonary disease. * Denominators in columns are number of patients with valid data at 12-month follow-up. 
† Difference (95% CI). ◆
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of the disease. It has been suggested,
for example, that the benefit of smok-
ing cessation may be greatest in
asymptomatic patients with measure-
able lung function impairment.29
The intervention tested in this
study showed promise in that there
were improvements in process of care,
but it did not have a measurable
impact on disease-related quality of
life, respiratory function or smoking
status. Given the burden that COPD
places on individuals and society, and
the importance of improved care in
the community, further research to
identify effective interventions,
including examination of their cost-
effectiveness, is needed. This could
involve more intensive interventions
to support smoking cessation, new
ways of delivering pulmonary rehabil-
itation, and intervention soon after
diagnosis of COPD.
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What is a QR code?
You may have noticed a strange symbol like the one here on some pages of the Journal (see pages 383 and 403) or in other 
places, such as on bus-stop ads or at the counter at cafes. These are called quick response (QR) codes, which work 
similarly to barcodes, in that they can digitally encode a range of information. They can be scanned by your tablet or 
smartphone and, in the Journal, they will take you directly to multimedia content such as podcasts without you having to 
type in a web address. The one on this page will take you to the MJA homepage.
How do I scan QR codes?
You need a tablet or smartphone and a QR reader to scan QR codes.
1) First download a free app that will scan QR codes. Go to the appropriate source of apps for your device (eg, Android 
Market, the App Store or Google Play) and download a free QR code reader such as i-nigma, RedLaser or Barcode 
Scanner.
2) Install the scanner app to your device.
3) With the scanner app open, hold your tablet or smartphone over the QR code.
QR codes in the MJA
You may see QR codes in the margins of MJA articles or in some advertising, which indicates that there is more 
information or multimedia content such as a podcast or video associated with that article. When you scan the QR code, 
your device will be taken to the website for that extra content, so that you can read, download or live stream the content.
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Flow diagram for the chronic obstructive pulmonary disease study, December 2006 – May 2009
Assessed for eligibility: 
261 GPs from 160 practices
1144 patients of 56 GPs from 44 practices 
assessed for eligibility and invited
66 losses before randomisation:
48 dropped out
14 lost contact
4 died
200 GPs excluded/refused 
to participate 
5 GPs consented but dropped out
before patient invitation 
517 patients provided written consent
GP practices randomised: 44 clusters
Baseline data obtained: 451 patients
Allocated to control
30 GPs in 22 clusters allocated
(all clusters received allocated intervention)
217 patients consented and allocated
All patients received intervention
(Mean cluster size, 9.9 patients; median, 
6.5 patients; range 2–29 patients)
Allocated to intervention
26 GPs in 22 clusters 
(all clusters received allocated intervention)
234 patients consented and allocated
52 did not receive intervention
(Mean cluster size, 10.6 patients; median, 
8.0 patients; range, 1–38 patients) 
Lost to follow-up
48 patients from 19 clusters
No clusters dropped out
26 patients dropped out
13 patients lost to follow-up
9 patients died
Lost to follow-up
73 patients from 14 clusters
2 clusters dropped out
39 patients dropped out
20 patients lost to follow-up
14 patients died
Analysed at 12-month follow-up
20 clusters analysed
161 patients analysed
(Mean cluster size, 8.1 patients; median, 
7.0 patients; range, 1–25 patients)
Analysed at 12-month follow-up
22 clusters analysed
169 patients analysed 
(Mean cluster size, 7.7 patients; median,
6.0 patients; range, 1–27 patients)
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Box  unedited, as supplied by the authors
 Intervention description 
Two intervention nurses with specific training worked in partnership with GPs, patients 
and other care providers over a six month period. Behaviour change was encouraged 
through use of motivational interviewing. Self management support was provided in 
the form of assistance with goal setting and action planning.
 
The intervention comprised 
• An initial home visit involving comprehensive assessment, including pre and post 
bronchodilator spirometry. 
• Development of a personalised care plan based on the recommendations of the 
COPDX guidelines using an electronic template provided. The care plan was based 
on the nurse assessment and discussion with the patient of goal setting and action 
planning. It the contained relevant components of smoking cessation, influenza and 
pneumococcal immunisation, pulmonary rehabilitation, medication review, 
nutrition, psychosocial issues, patient education, comorbidities and complications 
of COPD. Where spirometry did not confirm COPD the nurse discussed with the GP 
the actions following this and what parts of the care plan applied to these patients. 
• The nurse worked with the patient, their GP and other health professionals to 
implement the plan. This involved at least two home visits and five telephone 
contacts from the nurse and a minimum of two consultations with their GP. The 
nurse facilitated referral and teamwork with other services as needed such as 
smoking cessation program, pulmonary rehabilitation program, pharmacist, 
specialist physician, Action Plans for exacerbations were discussed and patients 
were encouraged to take these to their GPs for completion. 
• At the end of the six month intervention period progress against the goals in the plan 
were noted and a copy of the plan with these annotations provided to the GP. The 
completion of the plan was used to define that the patient had received the 
intervention. 
